Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
NiKang Therapeutics, Inc.
Cedars-Sinai Medical Center
Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris